Trial · NCT00049673

Thalidomide and Prednisone After Autologous Stem Cell Transplantation Multiple Myeloma

NCT00049673, Phase 3, Completed, NCIC Clinical Trials Group; results first posted 2020-10-05

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Thalidomide and Prednisone After Autologous Stem Cell Transplantation Multiple Myeloma. Trials, record NCT00049673. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00049673

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Thalidomide and Prednisone After Autologous Stem Cell Transplantation Multiple Myeloma
NCT number: NCT00049673
Status: Completed
Phases: Phase 3
Enrollment: 332 participants, actual
Lead sponsor: NCIC Clinical Trials Group
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: prednisone, thalidomide
First posted: 2003-01-27
Last updated: 2023-09-13
Results first posted: 2020-10-05

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Overall Survival	9 years	Number of patients died from any cause during the study.
Secondary	Disease Progression-free Survival	9 years	Number of patients with disease progression or death

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Overall Survival	9 years	Intention-to-treat population	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Disease Progression-free Survival	9 years	Intention-to-treat	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group8

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Units
Overall Survival	Prednisone	Death	50	Participants
Overall Survival	Observation	Death	61	Participants
Overall Survival	Prednisone	Alive	116	Participants
Overall Survival	Observation	Alive	105	Participants
Disease Progression-free Survival	Prednisone	Disease progression	100	Participants
Disease Progression-free Survival	Observation	Disease progression	127	Participants
Disease Progression-free Survival	Prednisone	Without progression	66	Participants
Disease Progression-free Survival	Observation	Without progression	39	Participants

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Prednisone	166
Overall Study	STARTED	Observation	166
Overall Study	COMPLETED	Prednisone	165
Overall Study	COMPLETED	Observation	163
Overall Study	NOT COMPLETED	Prednisone	1
Overall Study	NOT COMPLETED	Observation	3

Source ClinicalTrials.gov

Adverse events130

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Edema	Cardiac disorders	Prednisone	72	165
other	Edema	Cardiac disorders	Observation	29	163
other	Inner ear/hearing	Ear and labyrinth disorders	Prednisone	25	165
other	Inner ear/hearing	Ear and labyrinth disorders	Observation	4	163
other	Cushingoid appearance	Endocrine disorders	Prednisone	25	165
other	Cushingoid appearance	Endocrine disorders	Observation	0	163
other	Blurred vision	Eye disorders	Prednisone	31	165
other	Blurred vision	Eye disorders	Observation	5	163
other	Cataract	Eye disorders	Prednisone	18	165
other	Cataract	Eye disorders	Observation	1	163

1 to 10 of 130Source ClinicalTrials.gov

See all 130 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Prednisone	50	165
Total, all-cause mortality	Observation	61	163
Total, other adverse events	Prednisone	165	165
Total, other adverse events	Observation	158	163
Total, serious adverse events	Prednisone	5	165
Total, serious adverse events	Observation	2	163

Source ClinicalTrials.gov

Papers2

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
23297129	RESULT	PubMed
25302852	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Prednisone vs Observation: deaths from any cause	Trial comparisons
Prednisone vs Observation: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00049673

GET https://conductscience.org/api/trials/v1/NCT00049673/events?page=2

API reference For AI assistants